Press Release Archive
Press Releases
January 2020
01.06.2020 Research BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
December 2019
12.23.2019 Partnerships Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program 12.23.2019 Partnerships BioInvent announces selection of second target and extension of the research collaboration and license agreement with Pfizer Inc. 12.18.2019 Medicines U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy 12.18.2019 Finance Pfizer and Mylan Announce Two Future Viatris Board Members 12.17.2019 Finance Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts 12.17.2019 Partnerships Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders 12.16.2019 Medicines XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer 12.16.2019 Finance Research Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline 12.13.2019 Medicines Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease 12.12.2019 Medicines FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis 12.10.2019 Partnerships ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.